Doxorubicin /m^2

Phase 1Small molecule

Takeda

Doxorubicin /m^2 is one of 54 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaNot yet recruiting

Soft Tissue SarcomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

64 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

34 2

Adriamycin

Pfizer

Phase 3

27 3

Ifex

BBaxter Healthcare Corporation

Phase 3

32 4

Gemzar

Johnson & Johnson

Phase 3

11 5

Yondelis

AApotex Inc.

Phase 3

16 6

Farydak

Neulasta

3 8

Ellence

Pfizer

Phase 3

2 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 10

Keytruda

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Soft Tissue Sarcoma

NCT07027423

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Completed·NNYU Langone Health·Phase 2·NCT03742986·8 enrolled

Mantle Cell Lymphoma1 trial

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT00722137·487 enrolled

Soft Tissue Sarcoma1 trial

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

Not yet recruiting·UUniversity Health Network, Toronto·Phase 1·NCT07027423·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Doxorubicin /m^2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin /m^2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin /m^2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Takeda

Doxorubicin /m^2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Breast Cancer1 trial

Mantle Cell Lymphoma1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News